retatrutide phase 2 trial type 2 diabetes weight loss VisualAbstract: reduces body by 17.5% in patients with obesity Retatrutide as a Novel Treatment

Jenkins DJ, Wolever TM, Collier GR, Ocana A, Rao AV, Buckley G, et al

Buyer Takeaway: HumeCare explicitly positions itself around eventually not needing the service anymore

TriNetX cohort study (547,993 matched adults, published in JAAD International, 2026): GLP1 users were 40 percent more likely to develop nonscarring hair loss, 64 percent more likely to develop pattern thinning, and 76 percent more likely to experience stress-related shedding

(4) confirm a clear cancellation policy with no multi-month commitment

Add sterile water, bacteriostatic water, or PBS slowly down the vial wall and swirl gently do not shake

Judy Korner, an endocrinologist at NewYork-Presbyterian/Columbia University Irving Medical Center